-

TerSera® Receives National Recognition as a 2025 USA TODAY Top Workplace

original USA TODAY -- Top Work Places 2025 in the United States

USA TODAY -- Top Work Places 2025 in the United States

DEERFIELD, Ill.--(BUSINESS WIRE)--TerSera Therapeutics is proud to announce its recognition as a 2025 Top Workplace by USA TODAY, a prestigious award that highlights the company's achievements in cultivating an exceptional workplace culture. This follows TerSera’s recognition as a 2024 Healthcare Industry Top Workplace, a 2024 Chicago Tribune Top Workplace, and Culture Excellence Awards across a number of different categories including Leadership, Purpose & Values, Employee Appreciation and Well-Being, Professional Development, and Compensation & Benefits.

“We have built our patient and people-centered organization by trusting and empowering our team members and valuing each individual’s unique contributions,” said Edward Donovan, Chief Executive Officer of TerSera. “We are honored to be recognized as one of the top workplaces in the country, especially given the award is based on the sentiment of our employees. Thank you to our team of one-and-only professionals who make TerSera a great place to work.”

The Top Workplaces USA designation is based exclusively on employee feedback, gathered through an independent survey conducted by Energage, a leading HR technology and research firm. More than 42,000 organizations were invited to participate in the Top Workplaces survey, which recognizes organizations with 150 or more employees that have established best-in-class workplace cultures. Employee survey results were evaluated using research-backed metrics that measure workplace culture, leadership, and employee experience.

About TerSera Therapeutics

TerSera Therapeutics is a biopharmaceutical company with a focus in oncology and non-opioid pain management. Founded in 2016, TerSera is building new cornerstones of care through its portfolio of unique therapeutics, amplifying their ability to deliver meaningful outcomes for patients. For additional information, please visit TerSera.com and follow us on LinkedIn.

©2025 TerSera Therapeutics LLC. All rights reserved.

Contacts

Mark Leonard
mleonard@tersera.com
847-651-9682

Industry:

TerSera Therapeutics LLC

Release Versions
English

Contacts

Mark Leonard
mleonard@tersera.com
847-651-9682

More News From TerSera Therapeutics LLC

TerSera Therapeutics to Present Real-World Data on Intrathecal Ziconotide (PRIALT®) Prescription Patterns at ASPN 2025

DEERFIELD, Ill.--(BUSINESS WIRE)--TerSera Therapeutics LLC, a biopharmaceutical company with a focus in oncology, rare disease, and non-opioid pain management, announced today that its collaborative research on intrathecal ziconotide (PRIALT®) prescribing patterns has been accepted for presentation at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN) taking place July 17-20, 2025, in Miami, Florida. The poster will be presented by the primary author, Tolga Suvar, M....

TerSera® Presents New Real-World Evidence on Treatment Outcomes of Goserelin (ZOLADEX®) in Women with Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

DEERFIELD, Ill.--(BUSINESS WIRE)--TerSera Therapeutics LLC announced the presentation of new real-world analyses on the use of goserelin 3.6 mg and goserelin 10.8 mg in premenopausal women with breast cancer. These data were presented in a poster session at the 2024 San Antonio Breast Cancer Symposium, held December 10-13 in San Antonio, TX.1 A copy of the poster is available here. This was a retrospective, observational, non-inferiority study using structured, de-identified, patient-level data...

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

ROCKVILLE, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)--MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera Therapeutics LLC, a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain management, announced today that they have entered into an agreement in which TerSera will acquire global rights to MARGENZA® (mar...
Back to Newsroom